remyelination

Pipeline Raises $80M to Pursue Potential Myelin Restoring Therapy

Pipeline Therapeutics announced that it has raised $80 million in investor financing to develop neuroregenerative therapies for neurological disorders, including those like multiple sclerosis (MS) that are marked by the loss of myelin. The money will support the research and development of several candidate therapies, with three aimed at promoting and…

Mechanism Controlling Remyelination May Have MS Therapy Implications, Study Finds

Chemical modification of the protein eukaryotic elongation factor 1A1 (eEF1A1) regulates remyelination, a new study suggests, indicating that the processes regulating this protein may provide useful therapeutic targets for multiple sclerosis (MS). The study, “EEF1A1 deacetylation enables transcriptional activation of remyelination,” was published in Nature Communications.

MS News that Caught My Eye Last Week: Remyelination Research in Animal Models, Depression and Neurological Function, Ofatumumab Approval Moves Closer

In this column, I’ll be highlighting some of the research presented at this year’s Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held last week in West Palm Beach, Florida. #ACTRIMS2020 — Remyelination in Adult Animal Brains Possible via Cell Transplant, Study Says You’ll need…

Need to Know: Sleep and Myelin Plasticity

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the post “Researcher Receives $130K Grant to Study Sleep and MS” from Aug. 27,…